Agalaia Therapeutics is a biotech specialized in the development of new therapies to combat cancer disease.
Agalaia Therapeutics has raised €4.0M across 1 funding round from 3 investors, most recently a Seed round in Sep 2021. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-09-27 | Seed | €4.0M |
| Advent France Biotechnology,Crédit Mutuel Innovation,Pierre Fabre |
| View deal → |
